Loma Linda, California 92354

  • Carcinoma, Hepatocellular


This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared to Sorafenib alone will produce the best results for treating patients with Hepatocellular Carcinoma.


Inclusion Criteria: 1. Patients are candidates to receive both proton beam and sorafenib 2. Patients with tumor burden that exceeds San Francisco criteria Exclusion Criteria: 1. Patients who are candidates for surgical resection 2. Patients with tumor burden within Milan and/or San Francisco criteria 3. Patients who have contraindication to receive proton 4. Patients with contraindication to receive sorafenib including uncontrolled hypertension, coumadin treatment and prior intolerability to the drug 5. Patients treated previously by any locoregional treatment 6. Patients with prior liver transplant 7. Patients with child class C 8. Patients with model for end-stage liver disease (MELD) score of > 25 9. Patients with other comorbid diseases that may impact survival 10. Patients with ongoing alcohol intake 11. Patients with active sepsis 12. Patients with gastrointestinal bleeding within a week 13. Patients unwilling to sign informed consent form 14. Patients with history of noncompliance



Primary Contact:

Principal Investigator
Michael deVera, MD
Loma Linda University Medical Center

Diane Scavone
Phone: 909-558-3636
Email: DScavone@llu.edu

Backup Contact:


Location Contact:

Loma Linda, California 92354
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.